An interventional study of Yuping Yifei herbal formula and standardized Western medical treatment in COPD (Chronic Obstructive Pulmonary Disease) and Acute Exacerbation of Chronic Obstructive Pulmonary Disease, sponsored by First Affiliated Hospital of Ningbo University. Not yet recruiting at 4 sites in China. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by First Affiliated Hospital of Ningbo University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 407 studies in Pulmonary Disease, Chronic Obstructive with a site in China — 111 open to participants now, 128 under way, 16 of them phase 3. Pulmonary Disease, Chronic Obstructive · China.
Among the 407 studies in Pulmonary Disease, Chronic Obstructive with a site in China, this one is the 91st largest by planned enrollment of the 289 interventional ones that give a count, is one of 37 that started in 2026, is one of 121 with no phase, reaches primary completion later than 125 of the 127 other live ones, and was the 406th registered.
5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →111 of the 407 studies in Pulmonary Disease, Chronic Obstructive with a site in China are open now. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18+
Eli Lilly and Company · Sites in China, United States, Argentina and 15 more countries
Ages 40–75
Tiantian Li · Sites in China
Ages 40–80
Nanfang Hospital, Southern Medical University · Sites in China
Ages 30–85
Shanghai Pulmonary Hospital, Shanghai, China · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
407 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 42 · Phase 3 67 · Phase 4 33
First in 2000; this study’s year is marked. 37 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 360 is above the median of 62 across 3,845 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 160 across the 289 interventional studies, 500 across the 118 observational. Of the 183 that completed or were terminated, 47 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
162 of 407 have an industry lead sponsor. The 10 most frequent:
First Affiliated Hospital of Ningbo University is the lead sponsor of 29 studies on the registry; 26 are open to participants now.
First Affiliated Hospital of Ningbo University has 4 studies filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
30 of the studies in Pulmonary Disease, Chronic Obstructive with a site in China that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07464587Phase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease | 2027-02 |
| NCT07147946Phase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease | 2027-03 |
| NCT07658339Phase 3Haisco Pharmaceutical Group Co., Ltd.A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of HSK39004 Inhalation Suspension in Patients With COPD | 2027-06-11 |
| NCT05878769Phase 3Hoffmann-La RocheA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | 2027-06-30 |
| NCT07583849Phase 3Haisco Pharmaceutical Group Co., Ltd.A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase III Study of HSK39004 Inhalation Powder for the Treatment of COPD | 2027-09-30 |
Add all 30 to your calendar (.ics) → With an account.
Among the 407 studies in Pulmonary Disease, Chronic Obstructive with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This multicenter, randomized, open-label clinical trial will enroll 360 adults with chronic obstructive pulmonary disease (COPD): 240 with stable COPD and 120 hospitalized with an acute exacerbation (AECOPD). Participants will be stratified by disease stage and traditional Chinese medicine (TCM) syndrome. Within each syndrome stratum, they will be assigned to standardized Western medical treatment alone or the same treatment plus a syndrome-specific optimized herbal formula; selected strata will also include an innovative herbal formula group. Stable-phase participants will receive the study herbal treatment for 12 weeks, and AECOPD participants for 2 weeks. Both cohorts will be followed for 24 weeks. The study will assess lung function and exacerbations in stable COPD, and early dyspnea improvement and length of hospital stay in AECOPD. It will also assess symptoms, quality of life, TCM syndrome scores, safety, and biological markers.
Inclusion Criteria - Stable cohort:
Exclusion Criteria - Stable COPD cohort:
Inclusion Criteria - Hospitalized AECOPD cohort:
Exclusion Criteria - Hospitalized AECOPD cohort:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
24 participants with stable COPD and lung qi deficiency receive the optimized Yuping Yifei herbal formula plus standardized Western medical treatment for 12 weeks.
Drug: Yuping Yifei herbal formula · Drug: standardized Western medical treatment
24 participants with stable COPD and lung qi deficiency receive standardized Western medical treatment without the study herbal formula.
Drug: standardized Western medical treatment
24 participants with stable COPD and lung-spleen qi deficiency receive the optimized Liujun Fuzheng herbal formula plus standardized Western medical treatment for 12 weeks.
Drug: standardized Western medical treatment · Drug: Liujun Fuzheng herbal formula
24 participants with stable COPD and lung-spleen qi deficiency receive the innovative Qiyi Peitu herbal formula plus standardized Western medical treatment for 12 weeks.
Drug: standardized Western medical treatment · Drug: Qiyi Peitu herbal formula
24 participants with stable COPD and lung-spleen qi deficiency receive standardized Western medical treatment without the study herbal formula.
Drug: standardized Western medical treatment
24 participants with stable COPD and lung-kidney qi deficiency receive the optimized Shenqi Naqi herbal formula plus standardized Western medical treatment for 12 weeks.
Drug: standardized Western medical treatment · Drug: Shenqi Naqi herbal formula
24 participants with stable COPD and lung-kidney qi deficiency receive the innovative Fufei Gushen herbal formula plus standardized Western medical treatment for 12 weeks.
Drug: standardized Western medical treatment · Drug: Fufei Gushen herbal formula
24 participants with stable COPD and lung-kidney qi deficiency receive standardized Western medical treatment without the study herbal formula.
Drug: standardized Western medical treatment
24 participants with stable COPD and lung-kidney qi-yin deficiency receive the optimized Shengmai Runyuan herbal formula plus standardized Western medical treatment for 12 weeks.
Drug: standardized Western medical treatment · Drug: Shengmai Runyuan herbal formula
24 participants with stable COPD and lung-kidney qi-yin deficiency receive standardized Western medical treatment without the study herbal formula.
Drug: standardized Western medical treatment
24 hospitalized participants with AECOPD and phlegm-heat obstructing the lung receive the optimized Qinbei Qingfei herbal formula plus standardized Western medical treatment for 2 weeks.
Drug: standardized Western medical treatment · Drug: Qinbei Qingfei herbal formula
24 hospitalized participants with AECOPD and phlegm-heat obstructing the lung receive standardized Western medical treatment without the study herbal formula.
Drug: standardized Western medical treatment
24 hospitalized participants with AECOPD and phlegm-turbidity obstructing the lung receive the optimized Erchen Shunqi herbal formula plus standardized Western medical treatment for 2 weeks.
Drug: standardized Western medical treatment · Drug: Erchen Shunqi herbal formula
24 hospitalized participants with AECOPD and phlegm-turbidity obstructing the lung receive the innovative Banlou Kuanxiong herbal formula plus standardized Western medical treatment for 2 weeks.
Drug: standardized Western medical treatment · Drug: Banlou Kuanxiong herbal formula
24 hospitalized participants with AECOPD and phlegm-turbidity obstructing the lung receive standardized Western medical treatment without the study herbal formula.
Drug: standardized Western medical treatment
Stable COPD, lung qi deficiency: Huangqi 30 g, Dangshen 15 g, stir-fried Baizhu 12 g, Fangfeng 6 g, Wuweizi 6 g, Ziwan 9 g, and Sangbaipi 9 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 12 weeks, added to routine health education and guideline-based Western treatment.
Administer standardized Western medical treatment in accordance with the GOLD guidelines
Stable COPD, lung-spleen qi deficiency: Huangqi 30 g, Dangshen 15 g, stir-fried Baizhu 12 g, Fuling 12 g, Chenpi 9 g, ginger-processed Banxia 9 g, and honey-processed Gancao 6 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 12 weeks, added to routine health education and guideline-based Western treatment.
Stable COPD, lung-spleen qi deficiency: Huangqi 30 g, Dangshen 15 g, stir-fried Baizhu 12 g, Fuling 15 g, Shanyao 20 g, Yiyiren 20 g, and honey-processed Gancao 6 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 12 weeks, added to routine health education and guideline-based Western treatment.
Stable COPD, lung-kidney qi deficiency: Dangshen 20 g, Huangqi 30 g, salt-processed Duzhong 12 g, Buguzhi 9 g, Shanzhuyu 12 g, Wuweizi 6 g, Fuling 12 g, and ginger-processed Banxia 9 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 12 weeks, added to routine health education and guideline-based Western treatment.
Stable COPD, lung-kidney qi deficiency: Huangqi 30 g, Renshen 6 g, Yinyanghuo 9 g, Buguzhi 9 g, Shanzhuyu 12 g, Wuweizi 6 g, Gouqizi 15 g, and honey-processed Gancao 6 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 12 weeks, added to routine health education and guideline-based Western treatment.
Stable COPD, lung-kidney qi-yin deficiency: Dangshen 15 g, Zhemaidong 10 g, Wuweizi 6 g, Shudihuang 15 g, Shanzhuyu 12 g, Shanyao 20 g, Huangqi 30 g, and Danshen 15 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 12 weeks, added to routine health education and guideline-based Western treatment.
Hospitalized AECOPD, phlegm-heat obstructing the lung: Huangqin 9 g, Zhebeimu 10 g, Sangbaipi 12 g, Yuxingcao 20 g, Qingbanxia 9 g, Zisuzi 9 g, and honey-processed Mahuang 5 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 2 weeks, added to standardized Western treatment.
Hospitalized AECOPD, phlegm-turbidity obstructing the lung: ginger-processed Banxia 9 g, Houpo 9 g, Chenpi 9 g, Fuling 12 g, Zisuzi 9 g, Baijiezi 6 g, and Laifuzi 9 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 2 weeks, added to standardized Western treatment.
Hospitalized AECOPD, phlegm-turbidity obstructing the lung: ginger-processed Banxia 9 g, Houpo 9 g, Chenpi 9 g, Fuling 12 g, Gualoupi 9 g, Gualouren 6 g, Kuxingren 9 g, and Jiegeng 6 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 2 weeks, added to standardized Western treatment.
Change in FEV1 Percent Predicted at Week 24 (Stable COPD)
Absolute change from baseline in post-bronchodilator forced expiratory volume in one second as a percentage of the predicted value (FEV1%pred).
Time frame: Baseline (T0) and Week 24
Time to First Hospitalized COPD Exacerbation Through Week 24 (Stable COPD)
Time from T0 to the first acute COPD exacerbation requiring hospitalization. Exacerbations managed without hospitalization are not counted for this outcome.
Time frame: From baseline (T0) through Week 24
Number of Hospitalized COPD Exacerbations Through Week 24 (Stable COPD)
Count of acute COPD exacerbations requiring hospitalization from T0 through Week 24. Episodes treated only in outpatient or emergency settings without admission are not counted.
Time frame: From baseline (T0) through Week 24
Change in Dyspnea Numeric Rating Scale Score on Day 4 (AECOPD)
Absolute change from baseline in the average dyspnea numeric rating scale (NRS) score over the preceding 24 hours.
Time frame: Baseline (T0) and Day 4 (72 ± 24 hours after treatment initiation)
Proportion With at Least a 1-Point Improvement in Dyspnea NRS on Day 4 (AECOPD)
Proportion of participants whose average dyspnea NRS score over the preceding 24 hours decreases by at least 1 point from baseline.
Time frame: Baseline (T0) and Day 4 (72 ± 24 hours after treatment initiation)
Total Length of Hospital Stay for the Index AECOPD Admission
Number of days from admission for the index acute exacerbation to hospital discharge.
Time frame: From hospital admission to discharge for the index AECOPD episode
Change in COPD Assessment Test (CAT) Score
Change from baseline in CAT total score in the stable COPD and AECOPD cohorts.
Time frame: Stable COPD: baseline and Weeks 4, 8, 12, and 24; AECOPD: baseline, Days 4 and 7, and Weeks 2, 12, and 24
Change in TCM Syndrome Efficacy Score
Change from baseline in the syndrome-specific TCM symptom score using the appropriate stable-phase or AECOPD assessment scale.
Time frame: Baseline and scheduled assessments through Week 24
Change in St. George's Respiratory Questionnaire (SGRQ) Score
Change from baseline in SGRQ total score.
Time frame: Baseline, Week 12, and Week 24
Change in Modified Medical Research Council (mMRC) Dyspnea Grade
Change from baseline in the mMRC dyspnea grade, an ordinal measure of breathlessness, in stable COPD and hospitalized AECOPD participants.
Time frame: Stable COPD: baseline and Weeks 4, 8, 12, and 24; AECOPD: baseline, Days 4 and 7, and Weeks 2, 12, and 24
Change in Airway Wall Area Percentage on HRCT
Absolute change from baseline in airway wall area percentage (WA%) derived from quantitative high-resolution computed tomography.
Time frame: Baseline and Week 24
Change in Emphysema Index on HRCT
Absolute change from baseline in emphysema index derived from quantitative high-resolution computed tomography.
Time frame: Baseline and Week 24
Change in Airway Wall Thickness on HRCT
Absolute change from baseline in airway wall thickness derived from quantitative high-resolution computed tomography.
Time frame: Baseline and Week 24
Change in C-Reactive Protein Concentration
Absolute change from baseline in peripheral-blood C-reactive protein concentration as an inflammation marker.
Time frame: Stable COPD: baseline, Weeks 12 and 24; AECOPD: baseline, Weeks 2 and 24
Change in Interleukin-6 Concentration
Absolute change from baseline in interleukin-6 concentration measured in peripheral blood or induced sputum, where a safe sample is obtainable.
Time frame: Stable COPD: baseline, Weeks 12 and 24; AECOPD: baseline, Weeks 2 and 24
Change in Interleukin-8 Concentration
Absolute change from baseline in interleukin-8 concentration measured in peripheral blood or induced sputum, where a safe sample is obtainable.
Time frame: Stable COPD: baseline, Weeks 12 and 24; AECOPD: baseline, Weeks 2 and 24
Change in Tumor Necrosis Factor Alpha Concentration
Absolute change from baseline in tumor necrosis factor alpha concentration measured in peripheral blood or induced sputum, where a safe sample is obtainable.
Time frame: Stable COPD: baseline, Weeks 12 and 24; AECOPD: baseline, Weeks 2 and 24
Change in FEV1 Percent Predicted After AECOPD
Absolute change from baseline in post-bronchodilator FEV1 percent predicted among hospitalized AECOPD participants able to undergo safe and valid spirometry.
Time frame: Baseline when feasible, Weeks 12 and 24
Incidence of Adverse Events
Number and proportion of participants experiencing at least one adverse event during treatment and follow-up, with event type, severity, and relationship to study herbal treatment recorded.
Time frame: From baseline through Week 24
Incidence of Serious Adverse Events
Number and proportion of participants experiencing at least one serious adverse event during treatment and follow-up, with severity, management, outcome, and relationship to study herbal treatment recorded.
Time frame: From baseline through Week 24
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual participant data underlying the results reported in the main publication, including baseline characteristics, treatment allocation, and outcome data, will be available upon reasonable request. Direct personal identifiers will not be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Beginning after publication of the main study results, subject to applicable institutional and ethics requirements.
Access criteria: Qualified researchers may request access by submitting a research proposal to the study contact, together with ethics approval where applicable. Requests will be reviewed by the study team and relevant institutional or ethics bodies. Approved researchers will receive de-identified data under a data-use agreement. Re-identification and onward sharing are prohibited.
Start is estimated for Dec 2026; primary completion for Apr 2030, 39 months later.
Of 1,097 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 39 months is above that.
Counting every sponsor, half of 1,185 studies reached it within 22 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
First Affiliated Hospital of Ningbo University